Press releases
October 10, 2023
Our new CSR strategy
Javené, October 9, 2023
HTL, pioneer in the development and production of innovative pharmaceutical-grade biopolymers, announces its new corporate social responsibility (CSR) strategy. It aims to accelerate the company’s commitment to its entire ecosystem and transform its activity into a positive and sustainable force.
The strategy includes 19 commitments, divided into three priority areas: responsibility to preserve the environment, exemplarity with employees, and citizenship with civil society.
To see our most recent news,
Read more
news from us
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.
-
Articles June 21, 2024HTL Biotechnology at CPHI China 2024
CPHI China is one of Asia’s leading Pharma events for trading and networking with 3,500+ exhibitors and 90,000+ professionals from the pharmaceutical industry,
-
Articles June 13, 2024Discover our Quality Policy
At HTL Biotechnology, we believe in going beyond together to achieve the highest quality standards.